A $2.75 billion AI drug deal — and what it signals for the future of medicine
Insilico Medicine, a company that uses artificial intelligence to discover new drugs, has signed a deal worth up to $2.75 billion with pharmaceutical giant Eli Lilly.
Insilico Medicine doesn’t just use AI as a support tool. It has built algorithms designed to handle the entire drug discovery process: identifying biological targets, designing candidate molecules, and predicting their safety and effectiveness. That ambition is backed by substance — the company already has drug candidates in clinical trials, including one for idiopathic pulmonary fibrosis (a scarring of the lungs with no good existing treatments) that has reached early-stage human studies.
The deal with Eli Lilly, announced in early April 2026, works as a licensing agreement rather than an acquisition. Lilly gains access to selected candidates from Insilico’s pipeline. The headline figure of $2.75 billion is largely milestone-dependent — meaning it will only be paid out if drugs actually work and gain regulatory approval. The upfront payment is $115 million. That’s still a remarkable sum for a technology company that has yet to bring a single drug to market.
Faster and cheaper — but does it actually work better?
The promise of AI in drug development is straightforward: conventional drug research takes ten to fifteen years on average and costs billions, with most candidates failing in early stages or clinical trials. AI could accelerate candidate screening, improve success rates, and cut costs. But the track record of actually delivering clinically successful drugs through AI remains limited. DeepMind’s AlphaFold — which predicts the three-dimensional structure of proteins — is unambiguously revolutionary. For drug design itself, the evidence of AI outperforming traditional methods is still accumulating.
That Eli Lilly — the company currently dominating headlines with its blockbuster GLP-1 obesity drugs — is willing to commit this level of capital suggests the industry now considers the risk acceptable. Whether that confidence is warranted will depend on how Insilico’s candidates perform in larger trials over the coming years.
The longevity angle
Insilico has been explicit about its interest in aging. The company has applied its AI systems specifically to search for molecules that can intervene in aging processes, and aging-as-disease sits at the centre of its stated mission. This particular collaboration with Lilly covers the broader pipeline rather than anti-aging candidates specifically. But the precedent is significant: if AI-driven drug development becomes standard, it will also accelerate the search for interventions that directly target the biology of aging. The question is how quickly that acceleration will translate into something patients can actually access.